Want to join the conversation?
$MRK said that it is discontinuing the development of odanacatib, its investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use. $MRK has decided to discontinue development after an independent adjudication and analysis of major adverse cardiovascular events confirmed an increased risk of stroke.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.